Decay & Calibration-Time Math in Nuclear Pharmacy

A radiopharmaceutical dosage is never a fixed number — it is an activity that falls exponentially from the instant it is calibrated, so the dose actually administered depends entirely on getting the decay math and the calibration time right. In the nuclear pharmacy, that calculation is performed dozens of times a day, and an error in the decay factor, the calibration-time convention, or the dose calibrator reading flows straight through to the activity delivered to a patient. This article lays out the physics and the regulatory frame behind that daily task.

Introduction

Order a unit dose of fluorine-18 fluorodeoxyglucose (FDG) and the label tells you an activity at a stated calibration time — say, 15 millicuries at 7:00 AM. Inject it at 9:00 AM and the patient does not receive 15 millicuries. Over those two hours a substantial fraction has already decayed away. The gap between the labeled activity and the administered activity is not a rounding detail; for a short-lived positron emitter it can be a factor of two within a working morning.

Managing that gap — correctly, consistently, and with a traceable instrument — is the core quantitative skill of the nuclear pharmacy. This article covers the decay law and the decay factor, the pre-calibration and post-calibration conventions that trip people up, a fully worked FDG example, the role of the dose calibrator and its traceability, and the U.S. regulatory requirements for determining and documenting each dosage. DRPS supports facilities on these questions through its PET/CT and nuclear medicine physics and medical physicist consulting services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

The decay law

Radioactive decay is a first-order process: the rate of decay is proportional to the number of radioactive atoms present, which makes the activity fall exponentially with time. The governing equation is:

where $A(t)$ is the activity at time $t$, $A_0$ is the activity at a reference time, and $\lambda$ is the decay constant. The decay constant is fixed by the physical half-life $T_{1/2}$:

A short half-life means a large decay constant and fast decay. These half-lives are physical constants, tabulated authoritatively in nuclear decay-data compilations such as ICRP Publication 107 ⁴, and they do not change with temperature, chemical form, or how the dose is handled.

The decay factor

For practical work it is convenient to separate out the exponential term and call it the decay factor (DF):

The decay factor is simply the fraction of activity remaining after an elapsed time $t$. Because it is tied to half-lives, a few values are worth memorizing: after one half-life the decay factor is 0.5, after two it is 0.25, and after three it is 0.125. Multiplying a known activity by the decay factor moves it forward in time; dividing by the decay factor moves it backward in time.

Half-lives and decay constants of common radionuclides

The table below lists the physical half-lives (from standard nuclear decay data) and the corresponding decay constants for radionuclides handled routinely in nuclear medicine ⁴:

The span is enormous: a gallium-68 dose loses half its activity in a little over an hour, while a lutetium-177 therapy dose changes only about a tenth per day. The decay equation is identical in every case; only the half-life — and therefore the practical dispensing window — differs.

Key Technical Principles

Calibration time: pre-calibration versus post-calibration

Radiopharmaceuticals are not labeled with "the activity right now." They are labeled with an activity at a calibration date and time chosen by the manufacturer or radiopharmacy to match the expected use. Everything turns on where the moment of use sits relative to that calibration time.

• Post-calibration (drawing after the calibration time). The dose has decayed below its labeled value. The activity now is the labeled activity multiplied by the decay factor:
  $$A=A_{\text{cal}}{e}^{-\lambda \Delta t}$$
• Pre-calibration (drawing before the calibration time). The dose has not yet decayed to its labeled value, so the activity now is higher. The labeled activity is divided by the decay factor — equivalently, the sign of the exponent flips:
  $$A=A_{\text{cal}}{e}^{+\lambda \Delta t}$$

A common error is to apply the wrong direction — decaying a dose that should be built up, or vice versa — which for a short-lived nuclide produces a large activity error. The rule of thumb: after calibration, activity goes down; before calibration, it is higher. Related physics appears when the radionuclide is produced from a generator, where parent–daughter ingrowth, not simple decay, governs the available activity; see our discussion of the Mo-99/Tc-99m generator and transient equilibrium.

Worked example: an F-18 FDG unit dose

Consider a unit dose of F-18 FDG labeled 15.0 mCi calibrated to 7:00 AM, to be injected at 9:00 AM — an elapsed time of 2 hours, or 120 minutes, after the calibration time (post-calibration).

First, the decay constant for F-18 ($T_{1/2}=109.8$ min):

Then the decay factor over 120 minutes:

So the activity in the syringe at 9:00 AM is:

The dose has fallen to under half its labeled value in two hours. If the authorized user prescribed 7.0 mCi, the measured 7.03 mCi sits well within range. If, instead, the pharmacy needed to deliver 15.0 mCi at 9:00 AM, it would have to start from a pre-calibration activity of $15.0/0.469=32.0$ mCi at 7:00 AM. This is exactly why short-lived PET doses are calibrated close to scan time and why uptake-room scheduling and injection timing are tightly coupled — a theme explored in PET uptake time and its effect on quantification.

A decay-factor reference for F-18

Because F-18 decays so quickly, small timing differences matter. The table shows the decay factor and the residual activity of a 15.0 mCi (at calibration) F-18 dose at successive intervals after the calibration time:

A ten-minute slip in injection time is a measurable activity change for F-18, which is why the measurement is made close to administration rather than assumed from the label.

The dose calibrator makes it real

The decay math predicts an activity, but the activity that governs the patient dose is the one measured in a dose calibrator — a sealed, pressurized well-type ionization chamber — immediately before use. The calibrator must be set to the correct radionuclide, and its reading is only as good as its calibration and quality-control program. AAPM Report No. 181 describes the selection, use, calibration, and quality assurance of these instruments, covering the constancy, accuracy, linearity, and geometry tests that keep a reading trustworthy ⁵, and IAEA Technical Reports Series No. 454 sets out a quality-assurance framework for radioactivity measurement in nuclear medicine built on traceability to primary standards ⁶.

Traceability is not academic. According to published metrology studies, a well-controlled dose calibrator checked against a NIST-traceable source can hold accuracy, repeatability, and linearity deviations below 1.0% ¹¹, and establishing a full traceability chain shows that the calibrator's calibration factor is the dominant term in the activity uncertainty budget, contributing an average combined standard uncertainty near 1.57% ⁷. But when clinics rely on factory-set dial settings without traceability to a primary standard, measured activities can deviate by substantial amounts — one multi-hospital comparison for lutetium-177 found deviations up to 14.5% (median about 6%), which would imply systematic patient under-dosing ⁹. A national inter-laboratory comparison of clinical radionuclide calibrators for technetium-99m, fluorine-18, and lutetium-177 found most results within ±10% of the reference value, while also showing that many laboratories underestimated their own measurement uncertainty ⁸. This is the day-to-day reality behind our guide to dose calibrator quality control.

Supplier and receiver measurements

A unit dose is typically measured once by the supplier at production and again by the receiving pharmacy before use, with the receiver's value decay-corrected to the time of measurement. Reconciling the two readings — and treating the difference statistically rather than assuming one is "right" — is a recognized way to control measurement error and set defensible specification limits for the dispensed activity ¹⁰. The uncertainty of the half-life itself also propagates into any decay-corrected activity, so for a nuclide whose half-life is not precisely known the decay correction carries an additional, often under-appreciated, uncertainty term ¹².

Clinical Impact

Decay and calibration-time errors do not announce themselves — they show up downstream as degraded images or incorrect therapy activity.

In diagnostic imaging, an under-measured or over-decayed PET dose means fewer counts and a noisier image, or a standardized uptake value (SUV) biased by an incorrect assumed activity. Because SUV normalizes uptake to the injected activity and body size, an error in the decay-corrected administered activity feeds directly into the SUV, which can shift a quantitative read. Short-lived nuclides are the least forgiving: a scheduling delay that is trivial for a Tc-99m study is significant for F-18 and severe for Ga-68.

In radionuclide therapy, the activity is the dose. A systematic calibrator error of 10–15%, as seen when traceability is weak ⁹, translates directly into under- or over-treatment for a lutetium-177 or iodine-131 patient. Here the decay math and the traceable measurement are not a documentation formality; they set the delivered radiation dose.

For the whole department, consistent decay handling is what lets activities be compared across days, scanners, and sites. Harmonized, traceable measurement is the backbone of quantitative nuclear medicine, and it is the first thing that fails when calibration time is mishandled or the calibrator is trusted blindly.

Practical Optimization Tips

• Always read the calibration date and time on the label, not just the activity. The activity without its calibration time is meaningless for a short-lived nuclide.
• Confirm the direction of the correction. After the calibration time, multiply by the decay factor (activity is lower). Before it, divide (activity is higher). State which case you are in before you compute.
• Use the correct half-life and carry enough precision. Rounding F-18 to "two hours per half-life" instead of 109.8 minutes introduces an avoidable error over a long interval.
• Measure, then compare to prediction. The dose calibrator reading governs the administered activity; use the decay calculation as a sanity check, and investigate a reading that disagrees with the expected value by more than your quality-control tolerance.
• Keep the calibrator traceable and tested. Constancy, accuracy, linearity, and geometry checks per AAPM Report No. 181 keep the reading honest; factory dial settings alone are not a substitute for traceability ^{5, 9}.
• Mind the geometry. Volume and container differences change the calibrator response; use the geometry corrections the instrument's QC established, especially between vials and syringes ¹¹.
• Document the determination. Record the measured or calculated activity, the method, and the time — both because it is required and because it is the audit trail if a dose is ever questioned.

Regulatory Considerations

U.S. medical use of byproduct material is governed by the Nuclear Regulatory Commission under 10 CFR Part 35, with Agreement States administering equivalent programs. Two sections bear directly on decay and activity measurement.

• 10 CFR 35.63 — Determination and documentation of dosages. The licensee must determine and record the activity of each dosage before medical use. For a unit dosage, this may be done by direct measurement or by decay correction based on an activity determined by a manufacturer or preparer licensed under 10 CFR 32.72; for other-than-unit dosages, by direct measurement or a combination of measurement and calculation. Critically, paragraph (d) states that, unless the authorized user directs otherwise, a licensee may not use a dosage if it does not fall within the prescribed dosage range or if it differs from the prescribed dosage by more than 20 percent. That 20 percent is a limit on the prescribed-versus-administered dosage — not a numerical accuracy specification for the dose calibrator.
• 10 CFR 35.60 — Instrumentation to measure activity. The licensee must possess and use instrumentation to measure the activity of unsealed byproduct material before it is administered, and must calibrate that instrumentation in accordance with nationally recognized standards or the manufacturer's instructions. The regulation does not itself prescribe numeric test tolerances; those live in professional guidance such as AAPM Report No. 181 ⁵.

Beyond the NRC rules, USP General Chapter <825> establishes uniform standards for the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals, including handling and measurement before dispensing — the compendial backbone of nuclear pharmacy practice. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control programs, while Washington, DC and Delaware are regulated directly by the NRC for byproduct material. Facilities should connect decay-and-dosage practice to their broader program through radioactive material license support and documented quality control. For the determination requirement in its own right, see our guide to dose calibrator quality control.

Frequently Asked Questions (FAQs)

What is the radioactive decay law?

The activity of a radionuclide decreases exponentially with time: A(t) equals the initial activity A-zero multiplied by e raised to the power of negative lambda times t, where lambda is the decay constant. The decay constant equals the natural logarithm of 2 divided by the physical half-life, so a shorter half-life means faster decay. This is the single equation behind every dispensing calculation in the nuclear pharmacy.

What is the difference between pre-calibration and post-calibration activity?

Radiopharmaceuticals are labeled to a specific calibration date and time. A dose drawn after the calibration time (post-calibration) has decayed, so its activity is lower than the labeled value and is found by multiplying by the decay factor. A dose drawn before the calibration time (pre-calibration) has not yet decayed to the labeled value, so its activity is higher, and the labeled activity is divided by the decay factor to recover it.

What is the decay factor?

The decay factor is e raised to the power of negative lambda times the elapsed time. It is the fraction of activity remaining after a given interval. Over one half-life the decay factor is 0.5, over two half-lives it is 0.25, and over three half-lives it is 0.125. Multiplying a calibrated activity by the decay factor gives the activity at a later time.

Does the NRC require the dose calibrator to be accurate to within a specific percentage?

No. Under 10 CFR 35.63, a licensee may not use a dosage if it does not fall within the prescribed dosage range or differs from the prescribed dosage by more than 20 percent, unless the authorized user directs otherwise. That 20 percent is a limit on the prescribed-versus-administered dosage, not a numerical accuracy specification for the dose calibrator itself. 10 CFR 35.60 requires the instrument to be calibrated in accordance with nationally recognized standards or the manufacturer's instructions.

Why must activity be measured before administration?

10 CFR 35.60 requires a licensee to possess and use instrumentation to measure the activity of unsealed byproduct material before it is administered, and 10 CFR 35.63 requires the licensee to determine and record the activity of each dosage before medical use. Decay correction from a labeled calibration time is acceptable for unit dosages determined by a licensed manufacturer or preparer, but the activity still has to be established and documented before the dose is given.

How does half-life affect how far ahead a dose can be prepared?

The shorter the half-life, the faster the activity falls, so short-lived radionuclides must be measured and administered close to their calibration time. Fluorine-18, with a half-life near 110 minutes, loses roughly half its activity every two hours, while lutetium-177, with a half-life near 6.65 days, changes only a few percent over a working day. The decay math is the same; the practical dispensing window is very different.

What makes a dose calibrator measurement traceable and reliable?

A reliable measurement starts with a dose calibrator calibrated against nationally recognized standards and checked with a quality-control program covering constancy, accuracy, linearity, and geometry. Studies comparing clinic activity meters against primary activity standards have shown deviations ranging from under one percent for a well-controlled, traceable instrument to over fourteen percent when factory dial settings are used without traceability, which is why the calibration factor is the dominant term in the activity uncertainty budget.

Key Takeaways

• One equation runs the pharmacy. Activity falls as $A_0{e}^{-\lambda t}$, with $\lambda =0.693/T_{1/2}$; every dispensing calculation is an application of it.
• Calibration time is half the problem. Post-calibration doses are lower (multiply by the decay factor); pre-calibration doses are higher (divide). Getting the direction wrong is a large, avoidable error.
• Half-life sets the stakes. F-18 loses half its activity in under two hours; Lu-177 changes a few percent per day. Short-lived nuclides must be measured close to use.
• The measurement, not the label, governs the dose. A traceable, QC-tested dose calibrator is what turns a predicted activity into a defensible administered activity.
• The "20% rule" is a use limit, not a calibrator spec. 10 CFR 35.63(d) limits prescribed-versus-administered dosage; 10 CFR 35.60 requires calibration to recognized standards.
• Traceability matters clinically. Deviations from under 1% to over 14% have been reported depending on whether the instrument is traceably calibrated — directly affecting SUV accuracy and therapy dose.

Conclusion

The decay law is one of the simplest equations in physics, and in the nuclear pharmacy it is also one of the most consequential. Between the activity printed on a label and the activity delivered to a patient lie a decay factor, a calibration-time convention, and a dose calibrator reading — and an error in any of the three propagates straight to the dose. Short-lived PET tracers leave little margin for sloppy timing, and radionuclide therapy leaves none for an untraceable instrument. A disciplined program that reads the calibration time, applies the correction in the right direction, measures with a traceable and QC-tested calibrator, and documents the determination is what makes administered activity accurate, repeatable, and defensible.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and PET facilities with dose calibrator acceptance testing and quality-control program design; measurement traceability and uncertainty review; decay-and-dosage procedure development aligned with 10 CFR 35.60 and 35.63; SUV and quantitative-imaging support; and radioactive material license support — all performed by board-certified medical physicists.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. Whether you are standing up a new PET program or tightening an existing nuclear pharmacy workflow, a physics review ties the decay math, the instrument, and the documentation into one defensible process.

Related Resources

• Dose calibrator quality control
• Effective half-life and internal dosimetry
• The Mo-99/Tc-99m generator and transient equilibrium
• Radiochemical purity and TLC quality control
• Common PET and radiopharmaceutical-therapy isotopes
• PET/CT and nuclear medicine physics services
• Radioactive material license support

References

1. U.S. Nuclear Regulatory Commission. 10 CFR 35.63: Determination and documentation of dosages. nrc.gov
2. U.S. Nuclear Regulatory Commission. 10 CFR 35.60: Possession, use, and calibration of instruments used to measure the activity of unsealed byproduct material. nrc.gov
3. United States Pharmacopeia. USP General Chapter <825>: Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. Rockville, MD: USP. usp.org
4. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
5. Carey JE, Byrne P, DeWerd L, Lieto R, Petry N. (AAPM Task Group 181). The Selection, Use, Calibration, and Quality Assurance of Radionuclide Calibrators Used in Nuclear Medicine. AAPM Report No. 181. College Park, MD: American Association of Physicists in Medicine; 2012. doi:10.37206/137. doi.org
6. International Atomic Energy Agency. Quality Assurance for Radioactivity Measurement in Nuclear Medicine. Technical Reports Series No. 454. Vienna: IAEA; 2006. iaea.org
7. Robinson AP, Ferreira KM, Heetun W, et al. Establishing measurement traceability for quantitative SPECT imaging. EJNMMI Phys. 2025;12(1):58. doi:10.1186/s40658-025-00778-9. doi.org
8. Spagnuolo L, Capogni M, Fazio AA, De Felice P. National programme for the reliability of ionizing radiation measurements based on inter-laboratory comparisons (ILCs): ILC n°2 'radiopharmaceutical activities'. Appl Radiat Isot. 2024;212:111449. doi:10.1016/j.apradiso.2024.111449. doi.org
9. Hindorf C, Jessen L, Curkic Kapidzic S, et al. Traceable calibration with Lu-177 and comparison of activity meters at hospitals in Norway and Sweden. Phys Med. 2023;116:103170. doi:10.1016/j.ejmp.2023.103170. doi.org
10. Pereira WdP, Carvalheira L, Lopes JM, Aguiar PF, Moreira RM, Oliveira EC. Data reconciliation connected to guard bands to set specification limits related to risk assessment for radiopharmaceutical activity. Heliyon. 2023;9(12):e22992. doi:10.1016/j.heliyon.2023.e22992. doi.org
11. Hoang DX, Vu TD, Dan DV, Nhan NT. Assessment of the Performance of the Dose Calibrator Used in Radioactivity Measurement. Indian J Nucl Med. 2024;39(4):272-278. doi:10.4103/ijnm.ijnm_51_24. doi.org
12. Collins SM, Gilligan C, Pierson B, et al. Determination of the Tb-161 half-life. Appl Radiat Isot. 2022;182:110140. doi:10.1016/j.apradiso.2022.110140. doi.org